A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19
NCT06923137 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1
Last updated 2025-11-19
Summary
The purpose of this study is to learn about how well the yearly updates to the COVID-19 vaccine work in adults (age 18 years and above) with a healthy immune system (the body's cells, tissues and organs that work together to protect your body) and in children (age 6 months to 17 years).
This study will use a collection of insurance claims and state vaccine registry data called HealthVerity. All patient names and other identifying information is removed.
This study will include children who:
* Are 6 months of age to 17 years of age
* Are enrolled for at least 6 months in a row in a health insurance plan that provides data to HealthVerity
* Are enrolled for at least 6 months in a row in a prescription drug insurance plan that provides data to HealthVerity
* Live in the same US state for 6 months in a row
* Live in a US state that requires COVID-19 vaccine reporting and provides all vaccine history data to HealthVerity
* Do not have mismatches in sex and/or year of birth between any of the available datasets
* Do not have records of having had COVID-19 and/or any COVID-19 vaccine in the 90 days before the start of the study
This study will include adults who:
* Are 18 years of age and older
* Are enrolled for at least 12 months in a row in a health insurance plan that provides data to HealthVerity
* Are enrolled for at least 12 months in a row in a prescription drug insurance plan that provides data to HealthVerity
* Have lived in the same US state for at least 12 months
* Live in a US state that requires COVID-19 reporting and provides all vaccine history data to HealthVerity
* Do not have mismatches in sex and/or year of birth between any of the available datasets
* Do not have records of having had COVID-19 and/or any COVID-19 vaccine in the 90 days before the start of the study
This study will use the data that has already been collected, and no treatment or vaccine will be given in the study.
People who match the information above will be followed in the HealthVerity database for up to 6 months following the first day that a new COVID-19 vaccine is available. This information will be reviewed to see if any of the following happen:
* they had a COVID-19 vaccine
* they're diagnosed with COVID-19 in a doctor's office
* they visit the emergency department for COVID-19
* they visit urgent care for COVID-19
* they are hospitalized for COVID-19
The experiences of people who received a COVID-19 vaccine will be compared to the experiences of people who did not receive the vaccine. This will help to understand how well the Pfizer-BioNTech COVID-19 vaccine works at stopping COVID-19.
Conditions
- COVID-19 SARS-CoV-2 Infection
- COVID-19
- COVID-19 Infection
- Coronavirus Disease 2019 (COVID-19)
- COVID-19 (Coronavirus Disease 2019)
- COVID-19 Vaccination
- COVID-19 Vaccines
- SARS-CoV-2 Infection, COVID19
- SARS-CoV-2 Infection, COVID-19
Interventions
- DRUG
-
BNT162b2
BNT162b2
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Eligibility
- Min Age
- 6 Months
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-04-16
- Primary Completion
- 2030-10-31
- Completion
- 2030-10-31
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
NCT04368728 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
BNT162b2 Vaccination With 2 Doses in COVID-19 Negative Volunteers and With a Single Dose in COVID-19 Positive Volunteers
NCT04824638 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2
NCT04999111 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants
NCT04927065 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine Booster
NCT05602961 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
NCT05960097 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older
NCT04652102 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older
NCT06237296 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People
NCT05541861 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults
NCT04614948 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants
NCT04505722 ·Status: COMPLETED ·Phase: PHASE3
-
COVID-19 Bivalent Booster Megastudy
NCT05607082 ·Status: COMPLETED ·Phase: NA
-
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
NCT06585241 ·Status: RECRUITING ·Phase: PHASE4
-
COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay
NCT04452318 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older
NCT04904549 ·Status: COMPLETED ·Phase: PHASE3
-
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2
NCT05329220 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Ameliorating Effect of COVID-19 mRNA Vaccine in Individuals Immunized With Inactivated Vaccine
NCT04944381 ·Status: UNKNOWN ·Phase: NA
-
PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS
NCT05279365 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Immunogenicity and Safety of Comvigen (Bivalent) Vaccine
NCT05930730 ·Status: RECRUITING ·Phase: PHASE2
-
Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)
NCT06077149 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
NCT05997290 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population
NCT04649021 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years
NCT05329051 ·Status: UNKNOWN ·Phase: PHASE2
-
mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs
NCT05686161 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older
NCT03982199 ·Status: TERMINATED ·Phase: PHASE2